Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ALTERED EXPRESSION OF CD44 IN HUMAN PROSTATE-CANCER DURING PROGRESSION
Autore:
NAGABHUSHAN M; PRETLOW TG; GUO YJ; AMINI SB; PRETLOW TP; SY MS;
Indirizzi:
CASE WESTERN RESERVE UNIV,MED CTR,INST PATHOL,DEPT PATHOL,2085 ADELBERT RD CLEVELAND OH 44106 CASE WESTERN RESERVE UNIV,MED CTR,INST PATHOL,DEPT PATHOL CLEVELAND OH 44106 CASE WESTERN RESERVE UNIV,MED CTR,DEPT BIOSTAT & EPIDEMIOL CLEVELAND OH 44106
Titolo Testata:
American journal of clinical pathology
fascicolo: 5, volume: 106, anno: 1996,
pagine: 647 - 651
SICI:
0002-9173(1996)106:5<647:AEOCIH>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXTRACELLULAR-MATRIX; FLOW-CYTOMETRY; GLYCOPROTEIN; TUMOR; METASTASES; SURVIVAL; CELLS;
Keywords:
PROSTATE CANCER; CD44; METASTASES; IMMUNOHISTOCHEMISTRY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
M. Nagabhushan et al., "ALTERED EXPRESSION OF CD44 IN HUMAN PROSTATE-CANCER DURING PROGRESSION", American journal of clinical pathology, 106(5), 1996, pp. 647-651

Abstract

There is a great need for markers that distinguish slowly progressivefrom rapidly progressive prostate cancers in paraffin-embedded tissues. CD44, an adhesion molecule that has been useful for the prediction of prognosis in some other cancers, has not been described in prostatecancer. The expression of CD44 was investigated with the monoclonal antibody GKW.A3 in prostate cancer in formalin-fixed, paraffin-embeddedtissue sections of(1) whole prostates from 50 patients with 74 prostate cancers; and (2) lymph node metastases from 14 patients. Sixty percent of primary prostate cancers expressed CD44 moderately to strongly. No metastases expressed CD44 moderately to strongly; only 14% of metastases expressed even low levels of immunohistochemically detectable CD44. There is a difference between primary and metastatic prostate cancer (P < .0006) in the expression of CD44 and an inverse correlation (P < .05) between histological differentiation (Gleason grade) and the expression of CD44. The magnitude of the differential expression of CD44 in primary and metastatic prostate cancers suggests it should be investigated as an indicator of prognosis in a large prospective study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 14:00:26